We previously reported on Amgen’s complaint, in the Central District of California, seeking a declaratory judgment that MvasiTM (bevacizumab-awwb) does not infringe 27 Genentech patents, that those patents are invalid, and that one of the patents is unenforceable for inequitable conduct. Today, Amgen and Genentech submitted a stipulated briefing and hearing schedule on Genentech’s yet to be filed motion to dismiss Amgen’s complaint. Pursuant to the proposed schedule, Genentech will file a motion to dismiss on November 15, 2017, Amgen will file its opposition on December 21, 2017, Genentech will file its reply on December 28, 2017, and the Court will hear argument on January 8, 2018 at 8:30 am, subject to the Court’s approval.
Stay tuned to Big Molecule Watch for further updates.